Maria Serena Chiriacò - Nanotechnology

Author Information

Maria Serena Chiriacò is a distinguished researcher affiliated with the Institute of Nanotechnology, CNR NANOTEC, located in Lecce, Italy. Her research primarily focuses on nanotechnology and its applications in diagnostics and medical sciences.

Research Contributions

Maria Serena Chiriacò has made significant contributions to the field of nanotechnology, particularly in the development of non-invasive diagnostic assays and lab-on-chip platforms. Her recent work includes innovative approaches for cancer diagnostics and on-field virus analysis. She has also contributed to the understanding and treatment of various diseases through her research on chronic granulomatous disease and other immunological conditions.

Aliases

Maria Serena Chiriacò is also known by several aliases including M. S. Chiriaco, M Chiriaco, and Maria Chiriaco.

Publication and Citation Metrics

Citation Count	1604
H-index	25
Paper Count	93

Publications:

Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics

DOI: 10.1016/j.bios.2021.113698

Year: 2022

Editorial for the Special Issue on Emerging and Disruptive Next-Generation Technologies for POC: Sensors, Chemistry and Microfluidics for Diagnostics

DOI: 10.3390/mi13020181

Year: 2022

Lab-on-chip platform for on-field analysis of Grapevine leafroll-associated virus 3

DOI: 10.3390/MICROMACHINES2021-09580

Year: 2021

SMILE Platform: An Innovative Microfluidic Approach for On-Chip Sample Manipulation and Analysis in Oral Cancer Diagnosis

DOI: 10.3390/mi12080885

Year: 2021

Neonatal Manifestations of Chronic Granulomatous Disease: MAS/HLH and Necrotizing Pneumonia as Unusual Phenotypes and Review of the Literature

DOI: 10.1007/s10875-021-01159-4

Year: 2021

Immunological Aspects of X-Linked Chronic Granulomatous Disease Female Carriers

DOI: 10.3390/antiox10060891

Year: 2021

Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up

DOI: 10.3389/fped.2021.703853

Year: 2021

Corrigendum: Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient

DOI: 10.3389/fped.2021.757229

Year: 2021

Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient

DOI: 10.3389/fped.2021.702546

Year: 2021

Clinical, Immunological and Molecular Variability of RAG Deficiency: a Retrospective Analysis of 22 RAG Patients

DOI: 10.21203/RS.3.RS-584134/V1

Year: 2021

How Can Adhesion Forces Be Measured?

What are the limitations of X-Ray Reflectometry?

What are Interdigital Transducers (IDTs)?

What Does the Future Hold for Nanotechnology in Medicine?

How Can Nanotechnology Enhance Chemical Weapons?

What are the Challenges in Quantum Computing?

How do R&D costs contribute to economic losses?

How Can Companies Achieve Compliance?

What are the Challenges in Studying Crystalline Structures at the Nanoscale?

How can operational failures be mitigated?

Partnered Content Networks

Relevant Topics